LT3033344T - 5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska - Google Patents

5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska

Info

Publication number: LT3033344T
Authority: LT; Lithuania
Prior art keywords: methylene; tetrahydrofolic acid; hemisulfate salt; hemisulfate; salt
Prior art date: 2013-08-14

Application number

LTEP14758102.9T

Other languages

English (en)

Inventor

Rudolf Moser

Viola Groehn

Thomas Egger

Thomas Ammann

Original Assignee

Merck & Cie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-14

Filing date

2014-08-14

Publication date

2017-12-27

2014-08-14 Application filed by Merck & Cie filed Critical Merck & Cie

2017-12-27 Publication of LT3033344T publication Critical patent/LT3033344T/lt

Links

QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C07D475/14—Benz [g] pteridines, e.g. riboflavin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

LTEP14758102.9T 2013-08-14 2014-08-14 5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska LT3033344T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13004050.4A EP2837631A1 (en)	2013-08-14	2013-08-14	New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
PCT/EP2014/067447 WO2015022407A1 (en)	2013-08-14	2014-08-14	Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid

Publications (1)

Publication Number	Publication Date
LT3033344T true LT3033344T (lt)	2017-12-27

Family

ID=48998397

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP17190279.4T LT3287460T (lt)	2013-08-14	2014-08-14	5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska
LTEP14758102.9T LT3033344T (lt)	2013-08-14	2014-08-14	5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP17190279.4T LT3287460T (lt)	2013-08-14	2014-08-14	5,10-metilen-(6r)-tetrahidrofolio rūgšties hemisulfato druska

Country Status (27)

Country	Link
US (4)	US20160185787A1 (lt)
EP (3)	EP2837631A1 (lt)
JP (5)	JP6617104B2 (lt)
KR (2)	KR102410373B1 (lt)
CN (2)	CN108096200A (lt)
AU (2)	AU2014307872B2 (lt)
BR (2)	BR122020002802B1 (lt)
CA (1)	CA2921178C (lt)
CY (2)	CY1119694T1 (lt)
DK (2)	DK3033344T3 (lt)
EA (3)	EA201892729A1 (lt)
ES (2)	ES2871483T3 (lt)
HK (1)	HK1256262A1 (lt)
HR (2)	HRP20171895T1 (lt)
HU (2)	HUE054504T2 (lt)
IL (2)	IL244069B (lt)
LT (2)	LT3287460T (lt)
MX (2)	MX360355B (lt)
NO (1)	NO3033344T3 (lt)
NZ (2)	NZ745811A (lt)
PL (2)	PL3033344T3 (lt)
PT (2)	PT3287460T (lt)
RS (2)	RS61986B1 (lt)
SG (2)	SG10201801179VA (lt)
SI (2)	SI3033344T1 (lt)
WO (1)	WO2015022407A1 (lt)
ZA (1)	ZA201509204B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2837631A1 (en) *	2013-08-14	2015-02-18	Merck & Cie	New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en)	2016-02-17	2018-08-28	Merck & Cie	Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
EP3446703A1 (en) *	2017-08-24	2019-02-27	Isofol Medical AB	6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en)	2017-08-24	2019-02-27	Isofol Medical AB	[6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
ES2902051T3 (es)	2017-08-16	2022-03-24	Merck Patent Gmbh	Liofilizados estables que contienen ácido 5,10-metilen-(6R)-tetrahidrofólico y un ácido dicarboxílico
MX2020007009A (es) *	2018-01-05	2020-11-11	Isofol Medical Ab	Metodos para tratar canceres colorrectales metastasicos y colorrectales.
CN115335740A (zh) *	2020-03-30	2022-11-11	住友化学株式会社	层叠体
IL317395A (en)	2022-06-08	2025-02-01	Merck Patent Gmbh	Compositions containing disodium 10,5-methylene-(6R)-tetrahydrofolate
WO2023237482A1 (en)	2022-06-08	2023-12-14	Merck Patent Gmbh	Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate
EP4536186A1 (en)	2022-06-08	2025-04-16	Merck Patent GmbH	Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
EP4536185A1 (en)	2022-06-08	2025-04-16	Merck Patent GmbH	Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl
WO2023237485A1 (en)	2022-06-08	2023-12-14	Merck Patent Gmbh	Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2300505A (en) *	1940-10-31	1942-11-03	Bell Telephone Labor Inc	Selective system
WO1984004673A1 (en)	1983-05-20	1984-12-06	Bengt Gustavsson	A device for transferring a substance
DE3821875C1 (lt) *	1988-06-29	1990-02-15	Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH682664A5 (en) *	1991-10-15	1993-10-29	Eprova Ag	Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de)	1992-07-13	1994-11-15	Eprova Ag	5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
HU226998B1 (en)	2000-11-23	2010-04-28	Richter Gedeon Nyrt	Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
CH696628A5 (de) *	2002-02-26	2007-08-31	Eprova Ag	Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de)	2003-06-26	2008-03-31	Merck Eprova Ag	Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
JP2009518305A (ja) *	2005-12-02	2009-05-07	アドベントアールエックスファーマシューティカルズ，インコーポレイテッド	５，１０メチレンテトラヒドロ葉酸の安定な薬学的組成物
MY148217A (en)	2006-12-21	2013-03-29	Hoffmann La Roche	Polymorphs of a mglur5 receptor antagonist
JP5294968B2 (ja)	2009-05-01	2013-09-18	三星ダイヤモンド工業株式会社	スクライブヘッド及び該スクライブヘッドを用いたスクライブ装置
EP2768514B8 (en) *	2011-10-19	2019-06-19	Mercator Medsystems, Inc.	Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
EP2837766A1 (de) *	2013-08-14	2015-02-18	Sika Technology AG	Verfahren zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff sowie System zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff
EP2837631A1 (en) *	2013-08-14	2015-02-18	Merck & Cie	New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
JP6971761B2 (ja) *	2017-10-11	2021-11-24	株式会社Ｉｈｉプラント	タンクの構築方法

2013
- 2013-08-14 EP EP13004050.4A patent/EP2837631A1/en not_active Withdrawn
2014
- 2014-08-14 MX MX2016001834A patent/MX360355B/es active IP Right Grant
- 2014-08-14 PL PL14758102T patent/PL3033344T3/pl unknown
- 2014-08-14 US US14/912,328 patent/US20160185787A1/en not_active Abandoned
- 2014-08-14 EA EA201892729A patent/EA201892729A1/ru unknown
- 2014-08-14 DK DK14758102.9T patent/DK3033344T3/en active
- 2014-08-14 LT LTEP17190279.4T patent/LT3287460T/lt unknown
- 2014-08-14 SI SI201430529T patent/SI3033344T1/en unknown
- 2014-08-14 DK DK17190279.4T patent/DK3287460T3/da active
- 2014-08-14 KR KR1020217009189A patent/KR102410373B1/ko active Active
- 2014-08-14 NZ NZ745811A patent/NZ745811A/en unknown
- 2014-08-14 PL PL17190279T patent/PL3287460T3/pl unknown
- 2014-08-14 KR KR1020167006595A patent/KR102439605B1/ko active Active
- 2014-08-14 ES ES17190279T patent/ES2871483T3/es active Active
- 2014-08-14 RS RS20210630A patent/RS61986B1/sr unknown
- 2014-08-14 HU HUE17190279A patent/HUE054504T2/hu unknown
- 2014-08-14 NO NO14758102A patent/NO3033344T3/no unknown
- 2014-08-14 LT LTEP14758102.9T patent/LT3033344T/lt unknown
- 2014-08-14 AU AU2014307872A patent/AU2014307872B2/en active Active
- 2014-08-14 CN CN201810160334.3A patent/CN108096200A/zh active Pending
- 2014-08-14 RS RS20171337A patent/RS56910B1/sr unknown
- 2014-08-14 NZ NZ71782514A patent/NZ717825A/en unknown
- 2014-08-14 BR BR122020002802-5A patent/BR122020002802B1/pt active IP Right Grant
- 2014-08-14 MX MX2018013134A patent/MX382578B/es unknown
- 2014-08-14 SG SG10201801179VA patent/SG10201801179VA/en unknown
- 2014-08-14 HU HUE14758102A patent/HUE037615T2/hu unknown
- 2014-08-14 SI SI201431825T patent/SI3287460T1/sl unknown
- 2014-08-14 EA EA202091271A patent/EA202091271A3/ru unknown
- 2014-08-14 EP EP17190279.4A patent/EP3287460B1/en active Active
- 2014-08-14 CN CN201480044477.8A patent/CN105452250B/zh active Active
- 2014-08-14 CA CA2921178A patent/CA2921178C/en active Active
- 2014-08-14 PT PT171902794T patent/PT3287460T/pt unknown
- 2014-08-14 HR HRP20171895TT patent/HRP20171895T1/hr unknown
- 2014-08-14 BR BR112016002770-1A patent/BR112016002770B1/pt active IP Right Grant
- 2014-08-14 PT PT147581029T patent/PT3033344T/pt unknown
- 2014-08-14 SG SG11201601016PA patent/SG11201601016PA/en unknown
- 2014-08-14 EP EP14758102.9A patent/EP3033344B1/en active Active
- 2014-08-14 ES ES14758102.9T patent/ES2654474T3/es active Active
- 2014-08-14 WO PCT/EP2014/067447 patent/WO2015022407A1/en not_active Ceased
- 2014-08-14 EA EA201600172A patent/EA032179B1/ru not_active IP Right Cessation
- 2014-08-14 JP JP2016533926A patent/JP6617104B2/ja active Active
2015
- 2015-12-17 ZA ZA2015/09204A patent/ZA201509204B/en unknown
2016
- 2016-02-11 IL IL244069A patent/IL244069B/en active IP Right Grant
2017
- 2017-12-12 CY CY20171101298T patent/CY1119694T1/el unknown
2018
- 2018-09-03 JP JP2018164332A patent/JP6735321B2/ja active Active
- 2018-11-29 HK HK18115320.9A patent/HK1256262A1/zh unknown
- 2018-12-06 US US16/212,056 patent/US20190106431A1/en not_active Abandoned
- 2018-12-13 AU AU2018278943A patent/AU2018278943B2/en active Active
2019
- 2019-04-02 JP JP2019070293A patent/JP6764501B2/ja active Active
- 2019-09-08 IL IL269170A patent/IL269170B/en active IP Right Grant
2020
- 2020-05-11 JP JP2020083208A patent/JP7396960B2/ja active Active
2021
- 2021-04-27 CY CY20211100364T patent/CY1124076T1/el unknown
- 2021-05-12 HR HRP20210743TT patent/HRP20210743T1/hr unknown
- 2021-10-08 US US17/496,939 patent/US12122783B2/en active Active
- 2021-11-11 JP JP2021183793A patent/JP7710356B2/ja active Active
2024
- 2024-08-09 US US18/799,606 patent/US20240400574A1/en active Pending

Also Published As

Publication number	Publication date
RS56910B1 (sr)	2018-05-31
RS61986B1 (sr)	2021-07-30
IL269170B (en)	2020-09-30
CA2921178A1 (en)	2015-02-19
SI3287460T1 (sl)	2021-08-31
EP3287460B1 (en)	2021-02-24
HRP20171895T1 (hr)	2018-01-26
PT3033344T (pt)	2018-01-03
MX2016001834A (es)	2016-04-15
MX360355B (es)	2018-10-30
HUE054504T2 (hu)	2021-09-28
AU2014307872A1 (en)	2016-03-24
KR20160043054A (ko)	2016-04-20
ES2654474T3 (es)	2018-02-13
JP6735321B2 (ja)	2020-08-05
ZA201509204B (en)	2017-04-26
IL244069A0 (en)	2016-04-21
NZ717825A (en)	2019-11-29
EP3033344A1 (en)	2016-06-22
US20220024940A1 (en)	2022-01-27
JP2022024035A (ja)	2022-02-08
EP2837631A1 (en)	2015-02-18
SI3033344T1 (en)	2018-01-31
HK1217018A1 (zh)	2016-12-16
JP6764501B2 (ja)	2020-09-30
HUE037615T2 (hu)	2018-09-28
US20160185787A1 (en)	2016-06-30
BR112016002770B1 (pt)	2022-12-06
US20190106431A1 (en)	2019-04-11
JP7710356B2 (ja)	2025-07-18
PT3287460T (pt)	2021-05-27
HRP20210743T1 (hr)	2021-06-25
JP7396960B2 (ja)	2023-12-12
EA201600172A1 (ru)	2016-07-29
DK3287460T3 (da)	2021-05-03
KR20210038995A (ko)	2021-04-08
AU2018278943A1 (en)	2019-01-17
EA201892729A1 (ru)	2019-04-30
SG10201801179VA (en)	2018-03-28
EP3287460A1 (en)	2018-02-28
BR122020002802B1 (pt)	2022-11-29
AU2018278943B2 (en)	2019-12-05
CN105452250A (zh)	2016-03-30
JP2020128410A (ja)	2020-08-27
CY1119694T1 (el)	2018-04-04
IL244069B (en)	2019-09-26
AU2014307872B2 (en)	2018-09-27
EA032179B1 (ru)	2019-04-30
ES2871483T3 (es)	2021-10-29
CY1124076T1 (el)	2022-05-27
JP2019131579A (ja)	2019-08-08
CN108096200A (zh)	2018-06-01
DK3033344T3 (en)	2017-12-18
MX382578B (es)	2025-03-13
PL3287460T3 (pl)	2021-07-19
JP2018203763A (ja)	2018-12-27
BR112016002770A2 (pt)	2017-08-01
EP3033344B1 (en)	2017-09-27
US20240400574A1 (en)	2024-12-05
KR102410373B1 (ko)	2022-06-22
SG11201601016PA (en)	2016-03-30
JP2016528242A (ja)	2016-09-15
WO2015022407A1 (en)	2015-02-19
JP6617104B2 (ja)	2019-12-04
EA202091271A2 (ru)	2020-09-30
KR102439605B1 (ko)	2022-09-05
LT3287460T (lt)	2021-07-26
NZ745811A (en)	2020-05-29
HK1256262A1 (zh)	2019-09-20
IL269170A (en)	2019-11-28
PL3033344T3 (pl)	2018-02-28
CA2921178C (en)	2020-12-08
CN105452250B (zh)	2018-02-27
EA202091271A3 (ru)	2020-11-30
US12122783B2 (en)	2024-10-22
NO3033344T3 (lt)	2018-02-24

Publication	Publication Date	Title
IL269170B (en)	2020-09-30	The hemisulfate salt of tetrahydrofolic acid 5, 10 methylene (6r)
IL267343A (en)	2019-08-29	Pyrazole history as malt1 inhibitors
SG11201600062RA (en)	2016-02-26	Pyrimidine derivatives as kinase inhibitors
IL263653A (en)	2019-01-31	History of azabenzimidazole as PI3K inhibitors in the cell
IL247901A0 (en)	2016-11-30	Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
IL245660B (en)	2020-01-30	History of aminopyridines as tam family kinase inhibitors
EP2981535B8 (en)	2021-03-10	Urea derivatives useful as kinase inhibitors
EP3016953A4 (en)	2017-03-01	Purinone compounds as kinase inhibitors
IL240327B (en)	2019-01-31	New pyrazole derivatives
GB2516985B (en)	2015-07-29	Method of producing salt composition
ZA201808014B (en)	2020-02-26	Adenine derivatives as protein kinase inhibitors
IL239815A0 (en)	2015-08-31	Process for preparing derivatives of 4-methylpent-3-en-1-ol
GB2520791B (en)	2020-05-13	Method of producing derivatives of 1,3,5-triarylbenzene
EP3024427A4 (en)	2017-03-15	Derivatives of 2,2,6-trimethylcyclohexane-carboxylate
SG11201601135QA (en)	2016-03-30	3-substituted cyclopentylamine derivatives
HK1224675A1 (en)	2017-08-25	Purinone compounds as kinase inhibitors